4-(2-(1-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)ethyl)morpholine N-oxide | 1380243-86-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(2-(1-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)ethyl)morpholine N-oxide
• 英文别名: 4-Oxido-4-[2-[1-[4-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydroindazol-4-yl]ethyl]morpholin-4-ium
• CAS: 1380243-86-6
• 化学式: C₂₀H₂₄F₃N₃O₂
• 分子量: 395.425
• InChiKey: MQRMBFAEOCMUFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  45.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] 2-(1-PHENYL-4,5,6,7-TETRAHYDRO-1H-INDAZOL-4-YL)ETHYLAMINE DERIVATIVES USEFUL AS SIGMA RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE 2-(1-PHÉNYL-4,5,6,7-TÉTRAHYDRO-1H-INDAZOL-4-YL)ÉTHYLAMINE UTILES EN TANT QU'INHIBITEURS DES RÉCEPTEURS SIGMA
  申请人：ESTEVE LABOR DR

  公开号：WO2012072791A2

  公开（公告）日：2012-06-07

  The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to indazole derivatives of formula I and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use therapy and/or prophylaxis, in particular for the treatment of psychosis or pain.